Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anjianning (adalimumab) real-world study in autoimmune diseases
ChiCTR2500104254Phase 4Not yet recruiting
- Sponsor
- Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and plaque psoriasis (3 cohorts), sponsored by Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Primary endpoints: Proportion of patients achieving ACR 20, Proportion of patients achieving ASAS20 and 2 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2500104254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104254.